Search

Your search keyword '"Yamashita, Takashi"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Yamashita, Takashi" Remove constraint Author: "Yamashita, Takashi" Topic scleroderma, systemic Remove constraint Topic: scleroderma, systemic
40 results on '"Yamashita, Takashi"'

Search Results

1. Single cell analysis in systemic sclerosis - A systematic review.

2. ERG Regulates Lymphatic Vessel Specification Genes and Its Deficiency Impairs Wound Healing-Associated Lymphangiogenesis.

3. Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array.

4. Native T1 mapping in early diffuse and limited systemic sclerosis, and its association with diastolic function.

5. Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs.

6. Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma.

7. Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5 +/- ;Fli-1 +/- Mice.

8. Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease.

9. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.

10. Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis.

11. A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis.

12. Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy.

13. Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis.

14. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.

15. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.

16. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis.

17. An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis.

18. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.

19. Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon.

20. Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis.

21. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.

22. Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis.

23. Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency.

24. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.

25. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.

26. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.

27. Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.

28. A case of systemic sclerosis with linear scleroderma developing after fracture surgery.

29. Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.

30. Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.

31. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis.

32. Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis.

33. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.

34. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.

35. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.

36. Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability.

37. Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis.

38. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.

39. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.

40. Endothelin Receptor Blockade Ameliorates Vascular Fragility in Endothelial Cell–Specific Fli-1–Knockout Mice by Increasing Fli-1 DNA Binding Ability

Catalog

Books, media, physical & digital resources